Reversibility of Calcitriol-Induced Medial Artery Calcification in Rats With Intact Renal Function

Oxford University Press (OUP) - Tập 21 Số 3 - Trang 484-490 - 2006
Alicia Bas1, José I. López1, J. Pérez2, Mariano Rodríguez3, Escolástico Aguilera‐Tejero1
1Department of Medicina y Cirugia Animal, Universidad de Cordoba, Cordoba, Spain
2Department of Anatomia y Anatomia Patologica Comparadas, Universidad de Cordoba, Cordoba, Spain
3Unidad de Investigacion, Servicio de Nefrología, Hospital Universitario Reina Sofia, Cordoba, Spain

Tóm tắt

Abstract VC is an important clinical entity; however, very little information is available on its resolution. Induction and regression of calcitriol-induced VC was studied in 47 rats. After calcitriol withdrawal, there was a relatively rapid regression of VC mediated by an active cellular process. Introduction: Vascular calcifications (VCs) represent an important risk factor for cardiovascular death. Although VCs are prevalent in relevant diseases (e.g., chronic kidney disease, osteoporosis, diabetes), the reversibility of extraskeletal calcifications is an unresolved issue. This study was conducted to investigate (1) the in vivo effect of calcitriol on VC and (2) whether calcitriol-induced VC would regress after suppression of calcitriol treatment. Materials and Methods: The calcifying effect of calcitriol was studied in four groups of rats (n = 8) that received calcitriol (1 μg/kg, IP) for 2, 4, 6, and 8 days. The reversibility of VC was studied in three additional groups (n = 5) treated with 1 μg/kg of calcitriol for 8 days that were subsequently killed 1, 2, and 9 weeks after the last calcitriol dose. Aortic VC was assessed by histology and by quantification of aortic calcium and phosphorus content. The aortic wall was studied by histology and immunohistochemistry. Statistical analysis was performed by ANOVA and t-tests. Results: Calcitriol administration resulted in a time-dependent induction of VC, with aortic calcium and phosphorus being significantly increased at 6 and 8 days. Treatment with calcitriol for 8 days resulted in massive medial calcification of the aorta with a 10- to 30-fold increase in the aortic Ca and P content. After suppressing calcitriol administration, a progressive decrease in von Kossa staining and aortic Ca (from 32.8 ± 2.5 to 9.3 ± 1.8 mg/g of tissue, p < 0.001) and P (from 11.9 ± 1.2 to 2.7 ± 1.8 mg/g of tissue, p = 0.001) content was evidenced. Histology of the aortic wall showed monocytes adhered to the aortic endothelium and macrophages involved in the reabsorption of calcium deposits. Conclusions: Our results show that calcitriol treatment induces time-dependent VC. After calcitriol withdrawal, VC regress rapidly with aortic calcium and phosphorus decreasing by 75% in the course of 9 weeks. An active cellular process seems to be involved in regression of VC.

Từ khóa


Tài liệu tham khảo

Goodman, 2000, Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis, N Engl J Med, 342, 1478, 10.1056/NEJM200005183422003

Ganesh, 2001, Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients, J Am Soc Nephrol, 12, 2131, 10.1681/ASN.V12102131

Rubin, 2004, Vascular calcification and osteoporosis—the nature of the nexus, J Clin Endocrinol Metab, 89, 4243, 10.1210/jc.2004-1324

Schulz, 2004, Aortic calcification and the risk of osteoporosis and fractures, J Clin Endocrinol Metab, 89, 4246, 10.1210/jc.2003-030964

Schurgin, 2001, Increased prevalence of significant coronary artery calcification in patients with diabetes, Diabetes Care, 24, 335, 10.2337/diacare.24.2.335

Reaven, 2005, Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes, Diabetologia, 48, 379, 10.1007/s00125-004-1640-z

Diehm, 2004, Epidemiology of peripheral arterial disease, Vasa, 33, 183, 10.1024/0301-1526.33.4.183

Guerin, 2000, Arterial stiffening and vascular calcifications in end-stage renal disease, Nephrol Dial Transplant, 15, 1014, 10.1093/ndt/15.7.1014

Proudfoot, 2001, Biology of vascular calcification in vascular cells: Intima versus media, Herz, 26, 245, 10.1007/PL00002027

Demer, 2002, Vascular calcification and osteoporosis: Inflammatory responses to oxidized lipids, Int J Epidemiol, 31, 737, 10.1093/ije/31.4.737

Edmonds, 2000, Medial arterial calcification and diabetes mellitus, Z Kardiol, 89, 101, 10.1007/s003920070107

London, 1997, Atherosclerosis and arteriosclerosis in chronic renal failure, Kidney Int, 51, 1678, 10.1038/ki.1997.233

Ringe, 2004, Prevention and therapy of osteoporosis: The roles of plain vitamin D and alfacalcidiol, Rheumatol Int, 24, 189, 10.1007/s00296-004-0454-0

Wu-Wong, 2004, Vitamin D analogs as therapeutic agents: A clinical study update, Curr Opin Investig Drugs, 5, 320

Moe, 2003, Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product, Am J Nephrol, 23, 369, 10.1159/000073945

Price, 2004, Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat, J Biol Chem, 279, 1594, 10.1074/jbc.M305199200

Niederhoffer, 1997, Aortic calcification produced by vitamin D3 plus nicotine, J Vasc Res, 34, 386, 10.1159/000159247

Merke, 1987, Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro, Calcif Tissue Int, 41, 112, 10.1007/BF02555253

Inoue, 1988, 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+ -uptake by cultured vascular smooth muscle cells derived from rat aorta, Biochem Biophys Res Commun, 152, 1388, 10.1016/S0006-291X(88)80439-X

Jono, 1998, 1,25-Dihydroxivitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide, Circulation, 98, 1302, 10.1161/01.CIR.98.13.1302

Chen, 2004, Vascular calcification in chronic kidney disease, Semin Nephrol, 24, 61, 10.1053/j.semnephrol.2003.08.014

Demer, 2003, Mineral exploration: Search for the mechanism of vascular calcification and beyond, Artherioscler Thromb Vasc Biol, 23, 1739, 10.1161/01.ATV.0000093547.63630.0F

DiLeo, 2003, Cardiac and pulmonary calcification in a hemodialysis patient: Partial regression 4 years after parathyroidectomy, Clin Nephrol, 59, 59, 10.5414/CNP59059

Ramos-Vara, 1994, Reactivity of polyclonal human CD3 antiserum in lymphoid tissues of cattle, sheep, goats, rats and mice, Am J Vet Res, 55, 63, 10.2460/ajvr.1994.55.01.63

Price, 2000, Warfarin-induced artery calcification is accelerated by growth and vitamin D, Artherioscler Thromb Vasc Biol, 20, 317, 10.1161/01.ATV.20.2.317

Price, 2001, Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D, Arterioscler Thromb Vasc Biol, 21, 1610, 10.1161/hq1001.097102

Fernandez, 1994, Successful treatment of massive uremic tumoral calcinosis with daily haemodialysis and very low calcium dialysate, Nephrol Dial Transplant, 9, 1207, 10.1093/ndt/9.8.1207

Hwang, 1996, Reversible extraskeletal uptake of bone scanning in primary hyperparathyroidism, J Nucl Med, 37, 469

Sabeel, 2000, Complete resorption of massive soft tissue calcification in a hemodialysis patient after parathyroidectomy, Am J Nephrol, 20, 421, 10.1159/000013630

Maniscalco, 2004, Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy, Pathophysiology, 11, 95, 10.1016/j.pathophys.2004.06.001

Price, 2001, The amino biphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats, J Nutr, 131, 2910, 10.1093/jn/131.11.2910

Shao, 2003, Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice, J Biol Chem, 278, 50195, 10.1074/jbc.M308825200

Giachelli, 2005, Regulation of vascular calcification: Roles of phosphate and osteopontin, Circ Res, 15, 717, 10.1161/01.RES.0000161997.24797.c0

Krebs, 2004, Calcimimetics and hyperparathyroidism, Curr Opin Investig Drugs, 5, 1080

Robinson, 2005, Paricalcitol: A review of its use in the management of secondary hyperparathyroidism, Drugs, 65, 559, 10.2165/00003495-200565040-00008

Thông tin
Thông tin xuất bản

Oxford University Press (OUP)

Tập 21 Số 3

484-490

Thông tin tác giả